SCHEMBL2933540

SCHEMBL2933540

O=C(O)c1cccc2c1[nH]c1c3ccc(C(F)(F)F)cc3oc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 1/20 0.67
PIM1 P11309 2/20 0.41
PBRM1 Q86U86 2/20 0.41
PIM2 Q9P1W9 1/20 0.41
MPL P40238 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
ALOX12 P18054 1/20 0.41
KMT2A Q03164 1/20 0.41
GRM5 P41594 1/20 0.39
KDM4E B2RXH2 2/20 0.39
HSD17B10 Q99714 1/20 0.39
GFER P55789 2/20 0.38
MAPT P10636 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PTPRC P08575 2/20 0.37
PTPN2 P17706 2/20 0.37
PTPN1 P18031 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931043 0.86 KCNMA1 (0.52) KCNMA1PIM1ALDH1A1HPGDMEN1
SCHEMBL2925491 0.84 KCNMA1 (0.68) KCNMA1PIM1PIM2MPLALDH1A1
SCHEMBL2926491 0.81 KCNMA1 (0.50) KCNMA1PIM1PBRM1ALDH1A1CYP1A2
SCHEMBL2930924 0.81 KCNMA1 (0.49) KCNMA1PIM1PIM2MPLALDH1A1
SCHEMBL2924487 0.81 KDM4E (0.52) KCNMA1PIM1PBRM1ALDH1A1HPGD
SCHEMBL2925499 0.81 KCNMA1 (1.00) KCNMA1PIM1PBRM1PIM2MPL
SCHEMBL2932784 0.80 KCNMA1 (0.57) KCNMA1PIM1PBRM1PIM2ALDH1A1
SCHEMBL2929416 0.79 CA12 (0.53) KCNMA1PIM1PIM2ALDH1A1HPGD
SCHEMBL11738005 0.77 MPL (0.64) KCNMA1PBRM1MPLALDH1A1HPGD
SCHEMBL2930598 0.77 KCNMA1 (0.46) KCNMA1ALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180021303-A1 BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER CANBEX THERAPEUTICS LTD (GB) 2018-01-25 US disclosed
US-7812177-B2 Potassium channel opener having benzofuroindole skeleton ANYGEN CO., LTD. (KR) 2010-10-12 US disclosed
EP-1861092-B1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2010-09-15 EP disclosed
EP-1861092-A4 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2009-04-15 EP disclosed
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton ANYGEN CO., LTD. (KR) 2008-08-14 US disclosed
EP-1861092-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON Anygen Co., Ltd. (KR) 2007-12-05 EP disclosed
WO-2006096030-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO., LTD. (KR) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180021303-A1 BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER KCNMA1, KCNMB1, KCNA1 KCNMA1 1/4885PIM1 871/4885PBRM1 1825/4885
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton KCNJ2, KCNN3, KCNH2 KCNMA1 41/4885PIM1 3440/4885PBRM1 2170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.